Privium Fund Management B.V. Argenx Se Transaction History

Privium Fund Management B.V.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 28, 2022	SELL	$269.58 - $378.88 $3.45 Million - $4.85 Million	-12,801 Reduced 60.93%	8,208 $3.11 Million
Q1 2022 May 10, 2022	SELL	$254.45 - $351.06 $766,148 - $1.06 Million	-3,011 Reduced 12.54%	21,009 $6.62 Million
Q4 2021 Feb 09, 2022	BUY	$272.01 - $353.03 $6.53 Million - $8.48 Million	24,020 New	24,020 $8.48 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Privium Fund Management B.V., based on Form 13F filings with the SEC.

Stay updated on Privium Fund Management B.V. with notifications on news.